The Janus kinase inhibitor ruxolitinib reduces HIV replication in human macrophages and ameliorates HIV encephalitis in a murine model

Neurobiology of Disease

Volumn 92, Issue , 2016, Pages 137-143

  Haile, Woldeab B ^b   Gavegnano, Christina ^a,b   Tao, Sijia ^a,b   Jiang, Yong ^a   Schinazi, Raymond F ^a,b   Tyor, William R ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RUXOLITINIB; TENOFOVIR; ANTIVIRUS AGENT; JANUS KINASE INHIBITOR; PYRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; ASTROCYTOSIS; BLOOD BRAIN BARRIER; DRUG APPROVAL; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; ENCEPHALITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; ASTROCYTE; DISEASE MODEL; DRUG EFFECTS; GLIOSIS; MALE; METABOLISM; PATHOLOGY; PHYSIOLOGY; VIROLOGY; VIRUS ENCEPHALITIS;

ANIMALS; ANTIVIRAL AGENTS; ASTROCYTES; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; ENCEPHALITIS, VIRAL; GLIOSIS; HIV INFECTIONS; HIV-1; HUMANS; JANUS KINASE INHIBITORS; MACROPHAGES; MALE; MICE; MONOCYTES; PYRAZOLES; TENOFOVIR; VIRUS REPLICATION;

EID: 84958267604     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2016.02.007     Document Type: Article

References (29)

1. Avgeropoulos N., et al. SCID mice with HIV encephalitis develop behavioral abnormalities. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1998, 18:13-20.
2. Avgeropoulos N.G., et al. Potential relationships between the presence of HIV, macrophages, and astrogliosis in SCID mice with HIV encephalitis. J. NeuroAIDS 1998, 2:1-20.
3. Bovolenta C., et al. Constitutive activation of STATs upon in vivo human immunodeficiency virus infection. Blood 1999, 94:4202-4209.
4. Chen X., et al. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). J. Clin. Pharmacol. 2013, 53:721-730.
5. Cook-Easterwood J., et al. Highly active antiretroviral therapy of cognitive dysfunction and neuronal abnormalities in SCID mice with HIV encephalitis. Exp. Neurol. 2007, 205:506-512.
6. Cook J.E., et al. Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. Ann. Neurol. 2005, 57:795-803.
7. Dunfee R., et al. Mechanisms of HIV-1 neurotropism. Curr. HIV Res. 2006, 4:267-278.
8. Everall I., et al. Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J. Neurovirol. 2009, 15:360-370.
9. Fritz-French C., et al. The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model. J. Interf. Cytokine Res. 2014, 34:510-517.
10. Gavegnano C., et al. Cellular pharmacology and potency of HIV-1 nucleoside analogs in primary human macrophages. Antimicrob. Agents Chemother. 2013, 57:1262-1269.
11. Gavegnano, C., et al., 2014. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob. Agents Chemother. 014;58(4):1977-86.
12. Glass J.D., et al. Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlations with dementia. Ann. Neurol. 1995, 38:755-762.
13. Grant I., et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology 2014, 82:2055-2062.
14. Justicia C., et al. Activation of the JAK/STAT pathway following transient focal cerebral ischemia: signaling through Jak1 and Stat3 in astrocytes. Glia 2000, 30:253-270.
15. Koneru R., et al. Combined antiretroviral therapy reduces brain viral load and pathological features of HIV encephalitis in a mouse model. J. Neurovirol. 2014, 20:9-17.
16. Lee M., et al. Neurotoxins released from interferon-gamma-stimulated human astrocytes. Neuroscience 2013, 229:164-175.
17. Lichtfuss G.F., et al. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J. Immunol. 2012, 189:1491-1499.
18. Chevalier M., Petitjean G., Didier C., Dunyach-Remy C., Girard P.-M., Meyer L., Lavigne J.-P., Barre-Sinoussi F., Scott-Algara D., Weiss Laurence Soluble CD14 and IL-1ra Levels Predict the Immune Activation Set Point in the Absence of Microbial Translocation in Primary HIV Infection. 20th Conference on Retroviruses and Opportunistic Infections, Atlanta, GA 2013.
19. Rivera-Rivera L., et al. Inhibition of interferon response by cystatin B: implication in HIV replication of macrophage reservoirs. J. Neurovirol. 2012, 18:20-29.
20. Robertson K.R., et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010, 74:1260-1266.
21. Rumbaugh J.A., Tyor W. HIV-associated neurocognitive disorders: five new things. Neurol. Clin. Pract. 2015, 5:224-231.
22. Sas A.R. Cognitive dysfunction in HIV encephalitic SCID mice correlates with levels of Interferon-alpha in the brain. AIDS 2007, 21(16):2151-2159.
23. Sas A.R., et al. Interferon-alpha causes neuronal dysfunction in encephalitis. J. Neurosci. 2009, 29:3948-3955.
24. Schouten J., et al. HIV-1 infection and cognitive impairment in the cART era: a review. AIDS 2011, 25:561-575.
25. Sippy B.D., et al. Increased expression of tumor necrosis factor-alpha receptors in the brains of patients with AIDS. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 1995, 10:511-521.
26. Thames A., et al. B-85Genotype, CSF inflammation, and cognitive performance among African Americans and European Americans with HIV-infection. Arch. Clin. Neuropsychol. 2014, 29:568-569.
27. Thompson K.A., et al. Correlation between neurological progression and astrocyte apoptosis in HIV-associated dementia. Ann. Neurol. 2001, 49:745-752.
28. Tyor W.R., et al. A model of human immunodeficiency virus encephalitis in scid mice. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:8658-8662.
29. Verstovsek S., et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N. Engl. J. Med. 2012, 366:799-807.